Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation

G. Duray, Joachim R. Ehrlich, Stefan H. Hohnloser

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose of Review: To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation. Recent Findings: Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. The drug has - as its predecessor - multichannel-blocking efficacy and in addition vasodilating effects. It reduces the incidence of ventricular fibrillation in several experimental models. Dronedarone has undergone thorough clinical evaluation in various patient populations. In two large trials, the drug was shown to postpone the recurrence of atrial fibrillation after cardioversion relative to placebo. In a trial in unstable heart failure patients, there was excess mortality in the dronedarone arm. This trial was stopped prematurely and prompted the conduct of a large outcome study. The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. This large trial in more than 4600 patients revealed no signs of excess mortality or morbidity in patients receiving dronedarone. Summary: On the basis of the results of five international, multicenter, randomized clinical trials involving nearly 6300 patients, dronedarone was approved by the FDA for treatment of nonpermanent atrial fibrillation to reduce the risk of cardiovascular hospitalization.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalCurrent Opinion in Cardiology
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Atrial Fibrillation
Therapeutics
Hospitalization
Placebos
Electric Countershock
Amiodarone
Mortality
Anti-Arrhythmia Agents
Ventricular Fibrillation
dronedarone
Iodine
Pharmaceutical Preparations
Theoretical Models
Randomized Controlled Trials
Heart Failure
Outcome Assessment (Health Care)
Morbidity
Recurrence
Incidence
Population

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Dronedarone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dronedarone : A novel antiarrhythmic agent for the treatment of atrial fibrillation. / Duray, G.; Ehrlich, Joachim R.; Hohnloser, Stefan H.

In: Current Opinion in Cardiology, Vol. 25, No. 1, 01.2010, p. 53-58.

Research output: Contribution to journalArticle

Duray, G. ; Ehrlich, Joachim R. ; Hohnloser, Stefan H. / Dronedarone : A novel antiarrhythmic agent for the treatment of atrial fibrillation. In: Current Opinion in Cardiology. 2010 ; Vol. 25, No. 1. pp. 53-58.
@article{e1953ede0acc458c9f570ed4438586a3,
title = "Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation",
abstract = "Purpose of Review: To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation. Recent Findings: Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. The drug has - as its predecessor - multichannel-blocking efficacy and in addition vasodilating effects. It reduces the incidence of ventricular fibrillation in several experimental models. Dronedarone has undergone thorough clinical evaluation in various patient populations. In two large trials, the drug was shown to postpone the recurrence of atrial fibrillation after cardioversion relative to placebo. In a trial in unstable heart failure patients, there was excess mortality in the dronedarone arm. This trial was stopped prematurely and prompted the conduct of a large outcome study. The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. This large trial in more than 4600 patients revealed no signs of excess mortality or morbidity in patients receiving dronedarone. Summary: On the basis of the results of five international, multicenter, randomized clinical trials involving nearly 6300 patients, dronedarone was approved by the FDA for treatment of nonpermanent atrial fibrillation to reduce the risk of cardiovascular hospitalization.",
keywords = "Antiarrhythmic drugs, Atrial fibrillation, Dronedarone",
author = "G. Duray and Ehrlich, {Joachim R.} and Hohnloser, {Stefan H.}",
year = "2010",
month = "1",
doi = "10.1097/HCO.0b013e32833354e4",
language = "English",
volume = "25",
pages = "53--58",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Dronedarone

T2 - A novel antiarrhythmic agent for the treatment of atrial fibrillation

AU - Duray, G.

AU - Ehrlich, Joachim R.

AU - Hohnloser, Stefan H.

PY - 2010/1

Y1 - 2010/1

N2 - Purpose of Review: To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation. Recent Findings: Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. The drug has - as its predecessor - multichannel-blocking efficacy and in addition vasodilating effects. It reduces the incidence of ventricular fibrillation in several experimental models. Dronedarone has undergone thorough clinical evaluation in various patient populations. In two large trials, the drug was shown to postpone the recurrence of atrial fibrillation after cardioversion relative to placebo. In a trial in unstable heart failure patients, there was excess mortality in the dronedarone arm. This trial was stopped prematurely and prompted the conduct of a large outcome study. The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. This large trial in more than 4600 patients revealed no signs of excess mortality or morbidity in patients receiving dronedarone. Summary: On the basis of the results of five international, multicenter, randomized clinical trials involving nearly 6300 patients, dronedarone was approved by the FDA for treatment of nonpermanent atrial fibrillation to reduce the risk of cardiovascular hospitalization.

AB - Purpose of Review: To describe the electrophysiological profile and the clinical portfolio of dronedarone, a new multichannel-blocking antiarrhythmic drug developed for the treatment of atrial fibrillation. Recent Findings: Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. The drug has - as its predecessor - multichannel-blocking efficacy and in addition vasodilating effects. It reduces the incidence of ventricular fibrillation in several experimental models. Dronedarone has undergone thorough clinical evaluation in various patient populations. In two large trials, the drug was shown to postpone the recurrence of atrial fibrillation after cardioversion relative to placebo. In a trial in unstable heart failure patients, there was excess mortality in the dronedarone arm. This trial was stopped prematurely and prompted the conduct of a large outcome study. The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. This large trial in more than 4600 patients revealed no signs of excess mortality or morbidity in patients receiving dronedarone. Summary: On the basis of the results of five international, multicenter, randomized clinical trials involving nearly 6300 patients, dronedarone was approved by the FDA for treatment of nonpermanent atrial fibrillation to reduce the risk of cardiovascular hospitalization.

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Dronedarone

UR - http://www.scopus.com/inward/record.url?scp=74249117312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249117312&partnerID=8YFLogxK

U2 - 10.1097/HCO.0b013e32833354e4

DO - 10.1097/HCO.0b013e32833354e4

M3 - Article

C2 - 19881340

AN - SCOPUS:74249117312

VL - 25

SP - 53

EP - 58

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 1

ER -